Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: protamine sulfate; phenol; hydrochloric acid; glycerol; metacresol; sodium hydroxide; zinc oxide; water for injections; dibasic sodium phosphate heptahydrate - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: zinc oxide; sodium hydroxide; hydrochloric acid; dibasic sodium phosphate heptahydrate; protamine sulfate; phenol; glycerol; water for injections; metacresol - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; dibasic sodium phosphate heptahydrate; water for injections; zinc oxide; glycerol; metacresol - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, solution - excipient ingredients: hydrochloric acid; dibasic sodium phosphate heptahydrate; glycerol; metacresol; zinc oxide; sodium hydroxide; water for injections - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, solution - excipient ingredients: glycerol; sodium hydroxide; water for injections; hydrochloric acid; zinc oxide; dibasic sodium phosphate heptahydrate; metacresol - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - galcanezumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; water for injections; histidine; sodium chloride; polysorbate 80 - emgality is indicated for the prophylaxis of migraine in adults.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - galcanezumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine; water for injections; polysorbate 80; sodium chloride; histidine hydrochloride monohydrate - emgality is indicated for the prophylaxis of migraine in adults.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - ramucirumab, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: histidine; histidine hydrochloride monohydrate; water for injections; glycine; sodium chloride; polysorbate 80 - cyramza , in combination with paclitaxel, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluropyrimidine chemotherapy. cyramza, as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - ramucirumab, quantity: 100 mg - injection, intravenous infusion - excipient ingredients: sodium chloride; polysorbate 80; glycine; histidine hydrochloride monohydrate; water for injections; histidine - cyramza , in combination with paclitaxel, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluropyrimidine chemotherapy. cyramza, as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - somatropin, quantity: 6 mg (equivalent: somatropin, qty 18 iu) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; glycerol; hydrochloric acid; metacresol - humatrope is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.,humatrope is also indicated for the treatment of growth disturbances associated with gonadal dysgenesis (turner syndrome).,humatrope is also indicated for the treatment of adults with severe growth hormone deficiency defined as patients with known hypothalamic-pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a growth deficiency. in patients with childhood onset isolated gh deficiency (no evidence of hypothalamic-pituitary disease or cranal irradiation), two dynamic tests should be recommended, except for those having low igf-i concentrations less than or equal to 2 sds who may be considered for one test. the cut-off point of the dynamic test should be strict.,humatrope is also indicated for the treatment of growth retardation in prepubertal children with chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2.,humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years (see clinical trials). humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years. (see clinical trials)